AYTU

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational p...

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 10)

Following the market opening Thursday, the Dow traded down 0.12% to 30,033.62 while the NASDAQ rose 0.32% to 12,378.96. The S&P also rose, gaining 0.02% to 3,673.72.

During Q1, Aytu BioScience (NASDAQ: AYTU) brought in sales totaling $13.52 million. However, earnings decreased 46.39%, resulting in a loss of $3.56 million. Aytu BioScience collected $14.86 million in revenue during Q4, but reported earnings showed a $6.63 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Aytu BioScience's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Aytu BioScience posted an ROCE of -0.04%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on AYTUROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Aytu BioScience is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.For Aytu BioScience, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q1 Earnings Insight Aytu BioScience reported Q1 earnings per share at $-0.04/share, which beat analyst predictions of $-0.05/share.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Wednesday * 12 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The Company recently established a purchasing relationship with a U.S. supplier of Emergency Use Authorization (EUA) authorized antigen tests. Antigen tests rapidly detect the presence of the SARS-CoV-2 virus antigen via

Aytu BioScience (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 87.5 percent increase over losses of $(0.32) per share from the

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)